How is a Horse Like a Human?

They are both mammals, they share some identical genes, but they should not share the same drug: ivermectin.

What is ivermectin? Ivermectin is an avermectin – a type of naturally occurring drug, by way of fermentation – discovered through culture of the fungus Streptomyces avermitilis in 1967. It is an effective anti-parasitic drug whose discoverers won the Nobel Prize in 2015.

Ivermectin has been and is currently used to treat humans and animals for pathogen infestation or infection, and is part of the World Health Organization’s (WHO’s) Model List of Essential Medicines. Ivermectin may stop diseases like onchocerciasis or river blindness, an illness caused by helminths that damage capillaries of the eye; lymphatic filariasis, with accumulation of Wucheria worms in lymph vessels or glands; and scabies, a skin irritation caused by Sarcoptes mites. It may be administered by tablet, ointment, or injection in appropriate concentrations. 

In our crazy COVID-19 times, its use against viral infection has been tested in humans, and the drug is currently being utilized to treat COVID-positive patients in 24 developing countries, including India, Peru, and others.

“But SARS-CoV-2 is a virus, not a parasite, correct?” one might ask. “Why would one think a drug which affects growth of parasites could also inhibit growth of viruses?”

Viruses and parasites are different types of microbes. Viruses are considered non-living, as they require a host to reproduce. Parasites are classified in the same grouping as humans: eukaryotes. They may function alone, but thrive on nutrients and housing from a host. Both viruses and parasites may elicit a similar outcome from infection in the human body, namely clumping of blood cells, or microvascular occlusion.

The commonality of disease sequelae prompted investigators to question if ivermectin might prove useful for treatment of COVID-19 patients. The alteration in blood clotting may damage the lining, or endothelium, of capillaries. When damaged vessels surround the alveoli or functional units for gas exchange in lungs, victims are deprived of oxygen, hence the need for ventilators in severe COVID-19 cases.

As of July 2021, the National Institutes of Health (NIH) followed 16 of 55 studies for assessment of ivermectin’s effects on COVID-19 cases. It is thought that ivermectin interferes with one or more of 20 identified levels for infection, level one being binding virus to host cells (blocked by steric hindrance?), through host inflammatory responses, thus stopping viral progression.

Some studies have been discounted for small sample size, non-randomization of subjects, or incomplete follow-up. Dr. Omura, the ivermectin Nobel co-laureate, with colleagues, published a review with data showing a sizable decrease in morbidity and mortality for human COVID-19 patients treated with ivermectin.

Due to fervent wishes to stay safe, people have taken drugs intended for animal use. The Food and Drug Administration (FDA) recently tweeted, “you are not a horse. You are not a cow. C’mon ya’ll. Stop it.” The formulations and dosages for animal medications are NOT appropriate for humans. The ivermectin injection for cattle contains polyethylene glycol (PEG), a.k.a. antifreeze.

Ivermectin holds promise for SARS treatment: it has been approved, is inexpensive, and could be repurposed. But the best primary prevention for COVID-19 remains the Pfizer, Moderna, or J&J vaccine!

Programming Note: Listen to Julia Brodt report this story live today during Talk Ten Tuesdays, 10 Eastern.

Facebook
Twitter
LinkedIn

Related Stories

Leave a Reply

Please log in to your account to comment on this article.

Featured Webcasts

2026 IPPS Masterclass 3: Master MS-DRG Shifts and NTAPs

2026 IPPS Masterclass Day 3: MS-DRG Shifts and NTAPs

This third session in our 2026 IPPS Masterclass will feature a review of FY26 changes to the MS-DRG methodology and new technology add-on payments (NTAPs), presented by nationally recognized ICD-10 coding expert Christine Geiger, MA, RHIA, CCS, CRC, with bonus insights and analysis from Dr. James Kennedy.

August 14, 2025
2026 IPPS Masterclass Day 2: Master ICD-10-PCS Changes

2026 IPPS Masterclass Day 2: Master ICD-10-PCS Changes

This second session in our 2026 IPPS Masterclass will feature a review the FY26 changes to ICD-10-PCS codes. This information will be presented by nationally recognized ICD-10 coding expert Christine Geiger, MA, RHIA, CCS, CRC, with bonus insights and analysis from Dr. James Kennedy.

August 13, 2025
2026 IPPS Masterclass 1: Master ICD-10-CM Changes

2026 IPPS Masterclass Day 1: Master ICD-10-CM Changes

This first session in our 2026 IPPS Masterclass will feature an in-depth explanation of FY26 changes to ICD-10-CM codes and guidelines, CCs/MCCs, and revisions to the MCE, presented by presented by nationally recognized ICD-10 coding expert Christine Geiger, MA, RHIA, CCS, CRC, with bonus insights and analysis from Dr. James Kennedy.

August 12, 2025

Trending News

Featured Webcasts

The Two-Midnight Rule: New Challenges, Proven Strategies

The Two-Midnight Rule: New Challenges, Proven Strategies

RACmonitor is proud to welcome back Dr. Ronald Hirsch, one of his most requested webcasts. In this highly anticipated session, Dr. Hirsch will break down the complex Two Midnight Rule Medicare regulations, translating them into clear, actionable guidance. He’ll walk you through the basics of the rule, offer expert interpretation, and apply the rule to real-world clinical scenarios—so you leave with greater clarity, confidence, and the tools to ensure compliance.

June 19, 2025
Open Door Forum Webcast Series

Open Door Forum Webcast Series

Bring your questions and join the conversation during this open forum series, live every Wednesday at 10 a.m. EST from June 11–July 30. Hosted by Chuck Buck, these fast-paced 30-minute sessions connect you directly with top healthcare experts tackling today’s most urgent compliance and policy issues.

June 11, 2025
Open Door Forum: The Changing Face of Addiction: Coding, Compliance & Care

Open Door Forum: The Changing Face of Addiction: Coding, Compliance & Care

Substance abuse is everywhere. It’s a complicated diagnosis with wide-ranging implications well beyond acute care. The face of addiction continues to change so it’s important to remember not just the addict but the spectrum of extended victims and the other social determinants and legal ramifications. Join John K. Hall, MD, JD, MBA, FCLM, FRCPC, for a critical Q&A on navigating substance abuse in 2025.  Register today and be a part of the conversation!

July 16, 2025

Trending News

Prepare for the 2025 CMS IPPS Final Rule with ICD10monitor’s IPPSPalooza! Click HERE to learn more

Get 15% OFF on all educational webcasts at ICD10monitor with code JULYFOURTH24 until July 4, 2024—start learning today!

CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24